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Abstract
The need for antiretroviral therapy coupled with treatment of chronic co-morbidities places HIV-infected patients
at risk for polypharmacy. However, few studies have described overall pill burden among HIV-infected patients.
HIV-infected outpatients of the UNC Infectious Diseases Clinic were enrolled in this cross-sectional study.
Subjects were contacted prior to a scheduled appointment and asked to bring all their medications to the visit. Daily
total pill burden and medication type were recorded. 151 subjects were recruited: 76% male, 58% African
American, 97% receiving antiretrovirals (ARVs). Median age was 48 (IRQ: 42–54) years. The median number of
medications per subject was 8 (IQR: 6–11), and the median individual daily pill burden was 8 pills (IQR: 5–15): 3
pills (range: 2–5) for ARVs and 6 (range: 3–12.5) pills for non-ARVs. Duration of ART (per 2 years increase) and
more than 3 co-morbidities was significantly associated with high pill burden (over 10 pills per day) with adjusted
OR of 2.09 (95% CI, 1.14–3.84) and 8.04 (95% CI, 2.30–28.15), respectively. As patients with HIV age, strategies
to reduce pill burden and number of medications will become increasingly critical to maintaining adherence,
preventing medication errors, and serious drug–drug interactions.
Introduction
Antiretroviral therapy (ART) has led to substantialincreases in life expectancy and quality of life for HIV-
infected persons,1–4 and reduces transmission of the virus.5
As a result, treatment guidelines now recommend ART for all
HIV-infected individuals.6 While ART has become more
convenient, HIV infection still requires lifelong treatment. As
HIV-infected individuals experience life expectancies that
approach those without HIV, co-morbid conditions, includ-
ing those associated with aging, become increasingly prev-
alent.7–13 Consequently, patients with HIV are likely to be
prescribed a number of different medications both for HIV-
related and -unrelated indications. Such polypharmacy risks
drug interactions and overlapping toxicities, can be costly,
and as medication complexity increases, may affect treatment
adherence and virologic suppression.14–16
Estimates of medication burden among persons living with
HIV infection vary. Studies conducted between 1988 and
2010 examining cohorts in Switzerland and Canada, coun-
tries with centralized healthcare systems, found a relatively
high medication burden among HIV-infected persons, com-
pared to those without HIV, especially among older pa-
tients.10,17 However, less is known about the medication
burden and daily pill count for HIV-infected persons in the
US, where there is a greater diversity in patient populations
and less uniform access to HIV care and medication.
In this study, we quantified daily medication use, including
pill and medication number and pharmacologic categories of
medications taken, and examined factors associated with
medication burden. The study population included HIV-
infected patients receiving care at an outpatient clinic in the
southern US, a region with a high prevalence and incidence
not only of HIV but also co-morbidities such as diabetes
mellitus, obesity, and cardiovascular disease.18–21
Methods
Participants
We recruited participants from the University of North
Carolina at Chapel Hill (UNC) Center for AIDS Research
1Center for Infectious Diseases, School of Medicine, 2Lineberger Cancer Center, 3Eshelman School of Pharmacy, and 4Gillings School
of Global Public Health, UNC-Chapel Hill, Chapel Hill, North Carolina.
5School of Medicine, Wake Forest Baptist Medical Center, Winston-Salem, North Carolina.
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(CFAR) Clinical Cohort (UCHCC) study, a prospective clinic-
based cohort of HIV-infected patients.22 The vast majority
( > 90%) of UNC Infectious Diseases Clinic HIV-infected
patients have consented to participate in the UCHCC. Cohort
patients who were 18 years and older, English speaking, and
who previously agreed to be contacted by phone regarding
study opportunities were identified from weekly clinic ap-
pointment lists. Patients were not required to be on any
medications to participate. Eligible patients were contacted
by telephone within a week prior to their appointment to
ask if they would be willing to participate in the study. Those
who were interested were instructed to bring all their current
medications, including over-the-counter (OTC) drugs and
dietary supplements, to their upcoming clinical appointment.
At the appointment, written informed consent for study par-
ticipation was obtained. This project was approved by the
Biomedical Institutional Review Board at the University of
North Carolina at Chapel Hill.
Data collection
Pill burden. At the clinic visit, the medications brought in
by the patient were recorded and categorized. Patients who
did not bring their medications were not enrolled unless they
could produce a detailed medication list or were taking less
than five medications and could readily recall each medica-
tion name and dose (91% of participants brought in their
medications). Medication records were reviewed by at least
two pharmacists or physicians to categorize medications and
determine daily pill burden. Total medications included oral,
inhaled, injectable, and topical medicines that patients were
currently using. Pill burden was considered the number of
pills taken on a daily basis and only applied to oral medica-
tions (including oral medications taken through gastric
feeding tube). Each medication in non-OTC combination
forms was recorded individually as a separate medication,
while the pill burden was counted as one pill for one com-
bination pills regardless of the number of medications in this
combination (e.g., 1 tablet of fixed dose formulation of efa-
virenz, tenofovir, and emtricitabine was counted as three
medications and 1 pill for pill burden). Oral medications ta-
ken as needed (i.e., PRN) were included in the pill burden if
patients stated that they took the medication on a daily basis
with the lowest daily pill number counted. In addition, pa-
tients were required to answer five multiple-choice questions
regarding their perception of the pill burden (for questions
and responses, see Supplementary Table S1; supplementary
material is available online at www.liebertpub.com/apc).
FIG. 1. Study recruitment.
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Patient characteristics
Demographic information, insurance status at UNC HIV
care initiation, and HIV clinical history (nadir CD4 + cell
counts, duration of antiretroviral treatment, last CD4 + cell
count, and last HIV RNA levels) were obtained from the
UCHCC. Additionally, patients completed a brief question-
naire regarding demographic characteristics, including
questions about race/ethnicity, current medication insurance
status, and recent hospitalization. A physician investigator
reviewed the clinical charts of all patients to identify and
categorize co-morbid conditions. Co-morbid conditions oc-
curring within the prior year that were recorded included:
malignancy, diabetes mellitus, organ transplantation, hyper-
cholesterolemia/hypertriglyceridemia, hypertension, chronic
kidney disease, cardiovascular disease, chronic pain, psy-
chiatric disorders (i.e., depression, anxiety, bipolar), osteo-
porosis, and hepatitis C virus (HCV) co-infection.
Statistical methods
Patient demographic and clinical characteristics were de-
scribed using basic descriptive statistics. To identify patient
characteristics associated with having a high total pill burden,
we calculated unadjusted odds ratios (OR) and reported 95%
confidence intervals (CI) as measures of precision. High pill
burden was defined as the median cut-off of pills per day that
study patients indicated too many to take based on the
questionnaire. We also fit multivariable logistic regression to
identify factors associated with high pill burden. These
models were fit by including all factors associated with high
pill burden in unadjusted analyses ( p < 0.2), and removing
characteristics in a stepwise manner until only factors inde-
pendently predictive of high pill burden with a p value < 0.05
remained. We also employed a linear regression model for
the same factors in the multivariable logistic regression
model using pill burden as a continuous variable. We used
SAS version 9.2 (SAS Institute, Cary, NC) for all analyses.
Results
Patient characteristics
A total of 605 HIV-infected patients scheduled for routine
clinic appointments were screened between February and
July 2012, and 474 met the inclusion criteria and were con-
tacted by phone prior to a routinely scheduled clinic visit
(Fig. 1). Of the 131 not meeting the inclusion criteria, 108 had
indicated refusal to be contacted by phone when enrolled in
the cohort, and 23 were non-English speakers. Of the 474
eligible patients, 226 were unable to be reached by phone and
19 would either not be attending their clinic appointment or
could not bring in their medication. An additional 22 declined
participation, and 56 agreed to participate but did not com-
plete the study (i.e., missed scheduled clinic appointment).
Table 1 lists the demographic and clinical characteristics
of the 151 study participants who completed the interview, as
well as those of the patients who were screened but not en-
rolled. For both those screened but not enrolled and those
interviewed, most were middle-aged, male, and African
American. There were significantly more Hispanic patients in
the screened but not enrolled group than in interviewed group
(7% vs. 2%, p = 0.01) as patients who spoke only Spanish
were excluded. The insurance coverage at UNC HIV care
initiation was comparable between the interviewed patients
and the screened but not enrolled group. The majority of
interviewed patients were supported by public healthcare
plans (54%), followed by private insurance (22%); 21% of
patients had low (ADAP or hospital charity program only) or
no coverage for healthcare at the time of interview. Almost
all the enrolled patients were receiving ART, and 87% had
suppressed HIV RNA levels. In comparison, screened versus
enrolled patients were less likely to be currently receiving
ART (89% vs. 97%, p < 0.01) and be virologically suppressed
(78% vs. 87%, p = 0.01). Among the interviewed patients, co-
morbid conditions were common (Table 2). The median
number of co-morbidities patients had was 1 [interquartile
range (IQR): 1, 3], and the most commonly recorded conditions
Table 1. Demographic and Clinical
Characteristics of Study Patients







patients (n = 454)
Age (years) 48 (42–54) 47 (39–55)
Sex, male 114 (76%) 359 (79%)
Race
African American 88 (58%) 238 (53%)
Caucasian 49 (32%) 155 (34%)
Multiracial/others/
unknown
6 (4%) 17 (2%)
Native American 4 (3%) 8 (2%)
Latino 3 (2%) 34 (7%)
Asian 1 (1%) 1 (0%)
Insurance status at UNC HIV care initiation
Private 43 (28%) 125 (28%)
Public 39 (26%) 128 (28%)


















Other plans 4 (3%) NA
Unknown 2 (1%) NA
Prior ART use 149 (99%) 449 (99%)
Current ART use 146 (97%) 406 (90%)
Duration of ART, years 10 (4–16) 11 (5–16)
Nadir CD4 cell count,
cells/lL
126 (27–280) 174 (39–312)
Most recent CD4 cell
count, cells/lL
575 (385–779) 567 (355–768)
Most recent HIV RNA
level < 50 copies/mL
131 (87%) 352 (78%)
ADAP, AIDS Drug Assistance Programs; ART, antiretroviral
therapy; IQR, interquartile range; NA, not available.
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were hypertension (42%), psychiatric disorders (34%), hy-
percholesterolemia/hypertriglyceridemia (32%), and HCV co-
infection (20%).
Medication burden
Overall, the 151 participants were taking a total of 1394
medications, of which 847 (61%) were non-ART. The median
number of medications per patient was 8 (IQR: 6–11) and the
median individual daily pill burden was 8 pills (IQR: 5–15): a
median 3 pills (IQR: 2–5) were ART and 4 pills (IQR: 1–8)
were non-ART (Fig. 2). Patients over 50 years of age had a
median daily pill burden of 10 (IQR: 6.5–16), of which 3 pills
(IQR: 2–5) were ART and 6 (IQR: 3–12.5) were non-ART.
Among all patients receiving ART (n = 146), 80% were
treated with a NRTI plus an anchor agent: in 40% a protease
inhibitor (PI), in 30% a NNRTI, and in 10% an integrase in-
hibitor (InSTI). An additional 8% were on a NRTI plus both an
InSTI and PI, 2% were on a NRTI plus both a PI and a NNRTI,
and 3% were on a PI plus an InSTI only (Table 3). Eighty
participants (53%) were taking once-daily ART regimens and
31 (21%) participants were on a single tablet regimen.
For the 141 patients (93% of total interviewed patients)
receiving non-ART medications, these drugs were analgesics
in 52%, antihypertensives in 43%, vitamin/minerals in 40%,
antidepressants/antipsychotics/anxiolytics in 34%, and lipid-
lowering agents in 34% (Table 4). Twenty percent of the non-
ART medications were OTC, and 55% of patients were
taking OTC medications.
Factors associated with high daily pill burden
Overall, 64 (42%) patients were considered to have a high
pill burden (taking ‡ 10 pills per day—a threshold based
on patient survey response as described below). Factors
identified as being associated with high pill burden are listed
in Table 5. Gender, race, HCV co-infection, and last viral
load ‡ 50 copies/mL were not significantly associated with
high pill burden. Age (per 10 years increase), nadir CD4
(per 100 cells/lL decrease), duration of ART (per 2 years
increase), and number of co-morbidities were associated with
high pill burden with p values < 0.2. When these were in-
cluded in the multivariable regression model, duration of
ART (per 2 years increase) and number of co-morbidities > 2
remained significantly associated with high pill burden with
an adjusted OR of 2.09 (95% CI: 1.14–3.84, p = 0.02) and
FIG. 2. Box plots of daily
total medications, ART medi-
cations, non-ART medica-
tions, total pill burden, ART
pill burden, non-ART pill
burden per patient with me-
dian values, maximum values,
minimum values, and inter-
quartile ranges.
Table 2. Selected Co-Morbidities
in Study Participants
Selected co-morbidities N (%)
Hypertension 63 (42%)




Hepatitis C 30 (20%)
Chronic pain 27 (18%)
Chronic kidney disease 20 (13%)
Diabetes mellitus 16 (11%)
Coronary heart disease 9 (6%)
Malignancy 5 (3%)
Table 3. Antiretroviral Regimens
Regimens
Number of patients
taking the regimen (N = 146)
NRTI + one anchor agent 117 (80%)
NRTI + PI 58 (40%)
NRTI + NNRTI 44 (30%)
3 drug FDC 31 (21%)
NRTI + InSTI 15 (10%)
NRTI + NNRTI + PI 3 (2%)
NRTI + InSTI + PI 12 (8%)
NRTI + NNRTI + InSTI 2 (1%)
InSTI + PI 4 (3%)
NRTI + NNRTI + PI + InSTI 3 (2%)
Others 5 (3%)
FDC, fixed dose combination; InSTI, intergrase inhibitor;
NNRTI, non-nucleotide reverse transcriptase inhibitor; NRTI,
nucleotide/nucleoside reverse transcriptase inhibitor; PI, protease
inhibitor.
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8.04 (95% CI: 2.30–28.15, p < 0.01), respectively. The ad-
justed odds ratio for age (per 10 year increase) was 1.52 (95%
CI: 1.00–2.31, p = 0.05).
The multivariable linear regression model using pill bur-
den as a continuous variable revealed the same significant
factors associated with pill burden as logistic regression
model (duration of ART per 2 years increase, p = 0.005, co-
morbidity categories, p = 0.001 and there was a trend with
increasing age (per 10 year increase, p = 0.07).
Perceptions of pill burden
Fourteen percent of patients reported that their overall pill
burden was ‘‘too high’’ and 10% reported they were taking
medications ‘‘too often.’’ Ten percent of patients on ART
responded that their ART pill burden was ‘‘too high’’ and 7%
reported they were taking ART medications ‘‘too often.’’ The
median cut-off of pills per day that participants indicated was
too many to take was 10 pills (IQR: 5–20) (Supplementary
Table S1).
Discussion
In this cross-sectional study of patients living with HIV
infection engaged in medical care, we found polypharmacy to
be common. Half of the patients were taking 8 or more
medications, resulting in a median daily burden of 8 pills.
ART accounted for less than half of the medications taken,
and treatment for co-morbid hypertension, dyslipidemia,
mental health disorders, and pain accounted for the majority
of prescribed medication burden. Over-the-counter agents
and dietary supplements were being taken by 55% of the
patients. However, the vast majority of patients did not per-
ceive the total daily pill burden or medication dosing fre-
quency to be too high and considered a daily burden of 10 or
more pills per day to be excessive. Older age, duration of HIV
infection, and number of co-morbid conditions were each
associated with pill counts above this threshold.
The total pill burden for HIV-infected patients is influenced
by a number of epidemiologic and therapeutic factors. Fore-
most, the HIV-infected population is aging. It is projected that
by 2015, more than half of all persons living with HIV in
the US will be over 50 years of age.23 In addition, over 10% of
new HIV infections are among those older than 50 years.2 As
the proportion of persons living with HIV who are middle-
aged or older rises, so too does the risk of co-morbid conditions
requiring treatment; several studies suggest the risk of co- and
multi-morbidity among HIV-infected patients is greater than
that of age-matched controls without HIV.24–26 Treatment of
HIV is also now recommended for all patients, regardless of
CD4 + cell count, especially those aged 50 years or greater,
leading to more widespread prescription of ART. On the other
hand, HIV therapies are becoming simpler and co-formulation
of new and existing antiretroviral agents, in particular, reduces
pill number and dosing frequency.
Our results are remarkably concordant with a similar HIV
clinical cohort study in Alberta, Canada, where median total
daily pill burden in 2010 was found to be 6.7, with ART
accounting for 51% of medications taken.17 As in our study,
Table 4. Non-Antiretroviral (ART) Medication











Lipid lowering agents 46 (33%)
Acid secretion 25 (18%)
Insomnia 25 (18%)
Antivirals (non-HIV) 21 (15%)
Other antibiotic 17 (12%)






Hormone replacement 9 (6%)
Insulin 8 (6%)
Oral hyperglycemic agents 8 (6%)
Nausea/vomiting 7 (5%)
Anticoagulants 3 (2%)
Smoking cessation 3 (2%)
Table 5. Patient Demographic and Clinical Characteristics Associated with High Pill Burden
Characteristics Unadjusted OR (95% CI) p Value Adjusted OR (95% CI) p Value
Age, per 10 year increase 2.03 (1.41–2.94) < 0.001 1.52 (1.00–2.31) 0.05
Female 1.62 (0.77–3.41) 0.21
Caucasians 0.91 (0.46–1.82) 0.79
HCV co-infection 1.24 (0.56–2.78) 0.60
Nadir CD4, per 100 cells/lL decrease 1.01 (0.99–1.03) 0.16 1.01 (0.99–1.03) 0.26
Last CD4, per 100 cells/lL decrease 1.00 (0.99–1.01) 0.33
Duration of ART, per 2 years increase 2.92 (1.70–5.03) < 0.001 2.09 (1.14–3.84) 0.001
Number of co-morbidities
0 (control) 1 NA 1 NA
1–2 2.48 (0.92–6.72) 0.07 2.30 (0.80–6.61) 0.12
‡ 3 11.25 (3.57–35.50) < 0.001 8.04 (2.30–28.15) 0.001
Last viral load ‡ 50 copies/mL 0.89 (0.34–2.33) 0.82
Factors with p value < 0.2 in univariate analysis were included in multivariable logistic regression. (Age, nadir CD4, duration of ART,
number of co-morbidities).
ART, antiretroviral therapy; CI, confidence interval; OR, odds ratio.
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age, nadir CD4 + cell count, and duration of HIV infection
influenced pill burden. Similarly, our findings mirror those
from the Swiss HIV Cohort Study, which found an increasing
medication burden among HIV-infected patients accompa-
nying aging and the accumulation of co-morbid conditions.10
That study did not report a median daily pill burden and
examined data from 2008 through 2010.
While not perceived to be onerous by patients, the extent of
polypharmacy evident in this population has a number of
implications. The management of older patients with high pill
burdens may be challenging. A high percent of the patients
we studied were receiving antihypertensives, psychotropic
medications, and therapy for metabolic disorders. Some
widely used medications in these categories may have serious
drug–drug interactions (DDIs) with ART. For example, cer-
tain statin agents are contraindicated with ritonavir boosted
PIs due to increased risk of rhabdomyolysis.27 In addition,
although several studies28,29 indicate that older people have
better adherence to ART compared to younger patients, the
greater pill burden and treatment complexity attending poly-
pharmacy is known to challenge adherence.30–34 Pharma-
cists specializing in HIV services have been shown to improve
overall ART adherence and may be uniquely positioned
to identify patient-specific barriers to adherence.35–39 Our
findings suggest that the role of pharmacists can be im-
portant, not only for obtaining accurate ART and non-ART
medication reconciliation, but also identifying medication
discrepancies and preventing potential DDIs.
There are a number of strengths of our investigation in-
cluding direct ascertainment of medications actually being
taken via in person interviews during which patients were
asked to bring their medication for review. Over 91% of
patients brought their medications to the visit. All patients
had medication and co-morbidity data available within a
single electronic medical records system, facilitating data
collection. Selection of the participants was also designed to
be representative of the clinic population and accounted for
clinic health care provider and day of the week seen in the
clinic. The study was conducted in the US South, the region
of the country with the most people living with HIV and
where co-morbid conditions including diabetes and obesity
are also most prevalent.19,20 Our study also assessed per-
ceptions regarding medication burden among patients. The
responses provided useful information about the subjective
medication taking experience including a general acceptance
of the number of medications and pills being taken. The re-
spondents also provided a 10 pill per day threshold of ex-
cessive pill burden that can be useful in future assessments of
medication use in HIV-infected patients.
Limitations to our investigation include the study of pa-
tients within one HIV clinic, located within an academic
center. It could be that the medication and pill burden at other
types of practices might be different. However, the concor-
dance of our results with those from other countries supports
the generalizability of our findings. In addition, a significant
proportion of those screened for the study were not enrolled,
largely as a consequence of not meeting the inclusion criteria,
not being able to be reached by phone, or not attending their
scheduled clinic appointment. However, the generalizability
of our findings to the overall clinic population is supported by
the similar characteristics of the interviewed patients and
patients who were screened but not interviewed. This study
was not designed to assess or quantify medication adherence,
and while we aimed to ascertain the true pill burden, patients
may have brought with them medications that they were not
actually taking; therefore, in such cases our account of pill
burden would be an overestimate.
In summary, patients engaged in HIV care in a southern
specialty clinic were confirmed to be taking a median of 8
pills per day, with most of their medication burden comprised
of non-ART agents. Older age, co-morbidity, and longer
duration of HIV infection were associated with high pill
burden. As patients with HIV age, strategies to reduce pill
burden and number of medications, and avoidance of poly-
pharmacy will become increasingly critical to maintaining
adherence, preventing adverse events such as medication
errors, and serious drug–drug interactions.
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